Einzelnachweise

  1. ↑ 1,0 1,1 1,2 1,3 1,4 1,5 Fazekas F et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997; 349:589-93.
  2. ↑ 2,0 2,1 2,2 2,3 2,4 2,5 2,6 Achiron et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998; 50:398-402.
  3. ↑ Fazekas F et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: A dose-finding trial. Neurology 2008; 71:265-271.
  4. ↑ Gray O et al. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev 2003; CD002936.
  5. ↑ 5,0 5,1 5,2 Sorensen PS et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998; 50:1273-81.
  6. ↑ Teksam M et al. Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 2000; 42:885-9.
  7. ↑ 7,0 7,1 Fazekas F et al. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 2008; 71(4):265-71.
  8. ↑ van Engelen BG et al.Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Ann Neurol 1992; 32:834-5.
  9. ↑ Stangel M et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68:89-92.
  10. ↑ Noseworthy JH et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56:1514-22.
  11. ↑ Lewanska M et al. No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 2002; 9:565-72.
  12. ↑ Haas J et al. A dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler 2007; 13:900-8.
  13. ↑ Richards RG A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002; 6:1-73.
  14. ↑ 14,0 14,1 14,2 Bates D et al. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. BMJ 1978; 2:1390-1.
  15. ↑ 15,0 15,1 Millar JH et al.Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. BMJ1973; 1:765-8.
  16. ↑ 16,0 16,1 Paty DW. Double-blind trial of linoleic acid in multiple sclerosis.Arch Neurol 1983; 40:693-4.
  17. ↑ 17,0 17,1 Dworkin RH et al. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials. Neurology 1984; 34:1441-5.
  18. ↑ Bates D et al. A double-blind controlled trial of longchain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52:18-22.
  19. ↑ Ciccone A et al.Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008; CD006264.
  20. ↑ Miller H et al. Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin. Lancet 1961; 1:127–9.
  21. ↑ Ciccone A et al. Periodic intravenous methylprednisolone megadoses to prevent relapses in multiple sclerosis [Boli steroidei Preventivi per la Sclerosi Multipla (BPSM)]. Protocol approved by local Ethics Committee (Ospedale “Valduce”, Como, Italy) 1995.(BPSMGroup)
  22. ↑ Zivadinov R et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57:1239-47.
  23. ↑ Lus G et al. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 2004; 51:15-20.
  24. ↑ Munger KL et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60-5.
  25. ↑ Bennett M et al. Treatment of multiple sclerosis with hyperbaric oxygen therapy. Undersea Hyperb Med 2001; 28:117-22.
  26. ↑ Barnes MP et al. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial. J Neurol Neurosurg Psychiatry 1987; 50:1402-6.
  27. ↑ 27,0 27,1 Huntley A et al. Complementary and alternative therapies for treating multiple sclerosis symptoms: a systematic review. Complement Ther Med 2000; 8:97-105.
  28. ↑ Zajicek J et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362:1517-26.
  29. ↑ Oken BS et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62:2058-64.
  30. ↑ Motl RW et al. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult Scler 2008; 14(1):129-35.
  31. ↑ Mohr DC et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004; 328:73.